S4 - Deus Medical

Andarine (S4), initially developed by GTx Inc., emerged as a second-generation Selective Androgen Receptor Modulator (SARM). Designed to target muscle and bone tissue selectively, it was intended to treat muscle wasting and benign prostatic hypertrophy. Unlike anabolic steroids, Andarine’s structure minimizes androgenic effects while promoting muscle growth and fat reduction. It binds to androgen receptors, enhancing muscle mass and bone density with less impact on the prostate. Despite its therapeutic potential, research was discontinued, leaving Andarine as a gray-market compound for athletes.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about S4 by Deus Medical, consult with your doctor or healthcare professional.